INTRODUCTION
Drug designing and development are being attempted all over the world to meet every day's newer health complications, especially due to modern life style related diseases. Diabetes and cancer are the most dreaded diseases related to life styles of modern age. Apart from the cons of modern sedentary life style, we now a days, encounter a few more problems which lead to the serious outcomes due to several chronic and systemic diseases like -hormonal dysregulation, hyperglycaemia, metabolic syndrome and over all cancer. The present study relates the causes and their consequences with the contemporary interventions made by the scientific community. Most of the reasons, responsible for mentioned problems in human life style, are created by humans themselves. Behind the stated human diseases, excess use of chemicals and hormones do have a noteworthy presence. The result of this is accumulation of xenobiotic compounds in the human gut, liver and other tissues. This results in certain hormonal dysregulations in the body leading to various systemic diseases which in turn lead to certain mutations, sharing commonly contributory efficacy to result in carcinogenesis as well as diabetes. Apart from the ingestion of xenobiotic compounds and various other
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[12] CODEN (USA): JDDTAO cancer-causing agents in any or the other form, the mutation can take place due to the high quantity of ultra violet rays in the environment. Now, coming to the context of the present topic, we must say that using medications for what so ever reasons in an unsolicited manner is also largely responsible for various systemic disorders including the two diseases we are concerned about in this study. The unidentified side effects give reasons towards formation of various systemic and hormonal disorders. These disorders in turn give rise to diabetes and cancer.
Our focus would be to illustrate the reported links between the two of the most dreaded diseases in the light of previous studies on treating cancer by type-2 antidiabetic drugs by other investigators and ours as well 1, 2 . We shall look into the interventions made against cancer by some well documented anti-diabetic medicines. There are controversies of anticancer activity of certain antidiabetic drugs used in Type-2 diabetic patient having cancer and some are beneficial 2 . The multifunctional role of these drugs is mainly due to their involvement in different molecular signaling pathways.
As stated earlier, that from previous reports from the scientific world, it was understood that diabetes and cancer are the most dreaded real-world health problems in the present decade. In course of developing newer drugs to combat cancer, several established drugs have been trialled against cancer. This took place in connection with the common symptoms shared by different life style related diseases. Often two diseases are resulted by a common dysregulation of cell signalling pathways. It is obvious then, that any substance that re-stabilizes the regulation of the aforesaid cellular signalling pathways, can definitely act against both the concerned diseases. On similar thoughts, investigators have been searching anti-cancer potentials in type-2 anti-diabetic drugs since the two diseases do share a set of certain common cellular states.
Despite investigation into mechanisms linking Type-2 diabetes and cancer, there is a gap in knowledge about pharmacotherapy in cancer patients. Epidemiologic studies have shown that diabetic cancer patients on different anti-diabetic treatments have different survival. The clinically relevant question is, whether certain antidiabetic agents promote cancer while others inhibit cancer progression 1, 2, 3. Although insulin and glucose promoted cancer cell proliferation and contributed to chemoresistance, metformin and rosiglitazone suppressed cancer cell growth and induced apoptosis 3, 4 . Pioglitazone have been shown to induce apoptosis, as well as adipocyte differentiation 2, 5 . Dipeptidyl dipeptidase-4 (DPP-4) inhibitor, a newly developed another group of drug used in diabetes 6 . DPP-4 is a multifunctional cell surface protein that is widely expressed in most cell types including T lymphocytes 7 . There is no expression of DPP-4 in normal healthy thyroid, while it is highly expressed in papillary thyroid carcinoma 8 . The use of DPP-4 inhibitor together with glucagon like peptide-2 (GLP-2) led to increased proliferation as well as elevated migratory activity. Therefore, the DPP-4 inhibitor could increase the risk of promoting an already existing intestinal tumor and may support the potential of colon cancer cell to metastasize. Again DPP-4 inhibits malignant phenotype of prostate cancer cells by blocking bFGF signaling pathway 9 .
In the present investigation, we will be providing information about the efficacy of two groups of Type-2 anti-diabetic drugs (Metformin & Sitagliptin) in breast and liver cancer cells. In the present investigation we will compare the anticancer activity of these drugs at the level of different molecular signalling pathways.
MATERIALS AND METHODS

Cell line procurement and Culture
The cancer cell lines, MCF7 (Breast Cancer Cells) and HepG2 (Hepatocellular Carcinoma Cells) cells were kindly provided by Prof. Sanjay Ghosh, University of Calcutta. MCF-7 and HepG2 cells were maintained at 37˚C in a 5% CO 2 atmosphere in IMDM (GIBCO, Life Technologies, NY, USA) and DMEM (GIBCO, Life Technologies, NY, USA) respectively, with 10% FBS (GIBCO, Life Technologies, NY, USA), substituted with 50 units/ml penicillin and 50 mg/ml streptomycin (GIBCO, Life Technologies, NY, USA).
Chemicals and Reagents
Both of the drugs, sitagliptin and metformin, were purchased from SIGMA-ALDRICH (St. Louis, MO, USA). IMDM and DMEM culture media were purchased from GIBCO (Life Technologies, NY, USA), CellTiter-Blue ® for alamar blue assay was purchased from Promega corporation (Madison, WI, USA). RNeasy Mini Kit for RNA extraction and cDNA preparation kit were purchased from Qiagen, USA. The antibodies against PCNA, p21, p27, CDK4 and cyclin D were purchased from Abcam, USA, Cell Signalling Technologies, USA and Sigma (St. Louis, MO, USA). The anti-Rb secondary with HRP conjugate was also purchased from Sigma. The Caspase 3 Colorimetric Assay Kit was purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA).
Drug preparation for treatment
Sitagliptin were dissolved in dimethylsulfoxide (DMSO; SIGMA, St. Louis, USA) to prepare a primary stock solution of 25 mM and stored at -20˚C. The final concentrations for treatments (i.e., 10 μM, and 100 μM) were subsequently prepared by diluting the primary stock with respective media for different cell lines. The concentration of DMSO used in this study did not affect cell survival and protein phosphorylation. Metformin is completely water soluble and was prepared using ultrapurified DNase, RNase, mutagen free water as stock solution and then subsequent relevant concentrations required for the tests.
Alamar Blue assay
The inhibition of proliferation was assessed using Alamar Blue assay (THE CELL TITER-BLUE™ CELL VIABILITY ASSAY; Promega Corporation, Madison, USA). Cancer cell suspension was seeded to the wells of 96-well microtiter plates and treated with different concentrations of drugs. The plates were then incubated at standard cell culture conditions. 20μL of CelltiterBlue™ reagent per 100 μL of cell culture medium is ISSN: 2250-1177
[13] CODEN (USA): JDDTAO then added in each well and incubated for another 3 h. The organic substance Resazurin undergoes a blue shift to form Resorufin. Later, the colorimetric analysis was completed as per manufacturer's protocol and absorbance data were collected at 570 nm with a reference wave length of 600 nm, which reveals the inhibitory potential of the drugs.
Cytotoxicity test with normal human peripheral blood mononuclear cell (PBMNC)
Cytotoxicity test with normal human peripheral blood mononuclear cells (PBMC) was also performed. After informed consent, 5 mL of blood drawn from one of the authors was heparinized (10 U mL -1 ) and mixed with an equivalent quantity of normal saline. The homogeneous blood was coated on 3 mL of histopaque and centrifuged for 15-20 min at 1500 rpm at RT. PBMC were collected from the interface between histopaque and plasma, washed twice with normal saline and re-suspended in the culture medium. The cells were then maintained in standard culture conditions, in the presence or absence of the anti-diabetic drugs for 24 hrs. PBMC were stimulated with 2.5 mg mL -1 of phytohemoagglutinin and cytotoxicity was tested by alamar blue assay as described earlier 10 .
Western blot analysis
Cells were seeded for treatment onto 60 mm TC-treated plates (Nulgene, USA), washed with PBS at termination of treatment and lysed with RIPA lysis buffer (SigmaAldrich, USA) containing protease inhibitor cocktail (Sigma-Aldrich, USA). The whole cell lysate samples were then centrifuged at 10000 rpm for 30 minutes at 4˚C to collect the supernatant. Protein concentration is measured using Bradford reagent (Sigma-Aldrich, USA), and diluted 1:1 with SDS sample buffer (4% SDS, 20% glycerol, 0.5 M Tris-HCl (pH 6.8), 0.002% bromophenol blue). 50 μg of total protein, solubilised in SDS-sample buffer were resolved in each case in polyacrylamide (PAGE)-SDS gel system and electrotransblotted onto a PVDF membrane and blocked with 5% reconstituted non-fat dried milk (Sagar Skimmed Milk Powder, Amul, India). Membranes were incubated and probed with the following antibodies: rabbit-anti-PCNA (abcam, UK), rabbit-anti-p53, rabbit-anti-p21, rabbit-anti-p27, rabbit-anti-actin (all Cell Signaling Technologies, Leiden, The Netherlands) in a 1:1000 dilution or anti-cyclinD1 (Santa Cruz Biotechnology, UK). Primary antibodies were stained using HRPcoupled goat anti-rabbit or rabbit anti-mouse IgG and developed with ECL reagent (GE Healthcare Life Sciences, USA). Images were captured with the ImageQuant LAS 500 imaging system (GE Healthcare Life Sciences, USA).
Flow-cytometric analysis of apoptosis
The cells (110 with BD FACSuiteTM software. Flow cytometer was set for collecting data of 10,000 cells in each group. Flowcytometric reading will be taken using 488 nm excitation and band pass filters of 530/30 nm (for FITC detection) and 585/42 nm (for PI detection) 2 .
Fluorescence microscopy MCF7 and HepG2 cells were analysed for apoptogenic activity by Hoechst [Hoechst 33342; Invitrogen, USA] staining following standard protocol 11 . The cells, treated or untreated, were added to a 24 well plate so that there remains a cell number of 110 4 . After 72 h of treatment the cells were washed with PBS and Hoechst 33342, diluted in PBS, was added to the wells of culture plate. After 15-20 minutes of incubation the cells were washed again with PBS and adequate culture medium was added to cover the surface of the wells of the culture plate. The cells were then observed and photograph was taken using EVOS® FL Cell Imaging System (Life Technologies, USA).
Caspase 3 analysis using assay kit
110
7 number of Cancer cells were collected after drug treatment along with same number of normal untreated cells. Cell lysates were prepared and using the lysates their caspase-3 activities were determined using Sigma Caspase 3 Assay Kit (Sigma-Aldrich, USA) using 96 Well Plate Microassay Method. Drug-treated and untreated cells were lysed according to the manufacturer's protocol and the lysate including the kit chemicals were incubated and the absorbance was read at 405 nm wavelength using iMark™ Microplate Absorbance Reader (Biorad, CA, USA).
Statistical Analysis
Data were analysed by Student's t-test or ANOVA wherever required. Experiments were conducted thrice and each test was performed in multiple well/numbers. Data has been represented as mean±SD wherever applicable and p < 0.05 was considered significant.
RESULTS
Determination of IC50 of the drugs in cancer cell lines and cytotoxicity test with normal human peripheral blood mononuclear cell (PBMNC) after 24 hours of treatment
The IC50 of the anti-diabetic drugs were determined on the basis of 24 hours treatment by applying alamar blue assay (THE CELL TITER-BLUE™ CELL VIABILITY ASSAY; Promega Corporation, Madison, USA). Table 1 is showing the determined IC50 values for the antidiabetic drugs. shows that the drugs had affected the proliferative cancer cells much more than they inhibited the PBMNCs. Figure 1 describes the results thoroughly. The selective cytotoxicity of the anti-diabetic drugs to spare the normal cells suggests the usefulness of the drugs in exploiting their anti-cancerous properties in diabetic patients with breast and liver cancers. 
Cytotoxicity studies revealed metformin to be more effective as compared to sitagliptin
According to our analysis, all the drugs have more or less cytotoxic or cell growth inhibitory properties in MCF7 breast cancer cells and HepG2 hepatocellular carcinoma cells. The cytotoxicity data obtained has been expressed through the cell viability curve in figure 2A and 2B. Figure 2A explains the growth inhibitory properties of the anti-diabetic drugs on MCF7 breast cancer cells. From the apparent tendency of the curve it is clear, that the drugs pioglitazone and metformin have better effective cytotoxicity as compared with that of sitagliptin. The apparent tendency of cytotoxicity curve is almost similar in case of the other cell line we tested, the HepG2 ( Figure 2B ). But it seems the drugs are more efficient inhibitors of MCF7 cells.
Analytical information, obtained from the detailed data, suggests that in case of both the cell lines, significant decrease in the viability of the cancer cells was observed only after 48 hours of treatment. After 48 hours, the cytotoxicity by sitagliptin was similar to that of by the other two drugs, especially in HepG2 cell line. But it was not the same by its measure in following treatment hours, 72 hours and 96 hours. After 96 hours, where the viability after treatment with sitagliptin 10 μM and 100 μM are 88.29% and 79.89% it deepens to 62.37% with 1mM metformin. In case of MCF7 cell line the cytotoxicity of sitagliptin is slightly enhanced; 87.82% and 78.92% with sitagliptin 10 μM and 100 μM respectively. The cell viability by metformin treatment has drastically fallen to 40.13% by metformin 1mM. Figure 2C and figure 2D shows the growth of MCF7 and HepG2 cells respectively, in culture dishes under the phase contrast microscope. Fluorescent staining of cancer cell nucleus showed the cytotoxic efficacy of anti-diabetic drugs on cancer cells
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The cytotoxicity of the anti-diabetic drugs on cancer cell lines was re-confirmed via fluorescent staining. The live cell nuclei were stained using Hoechst 33342 nuclear stain and the fluorescent image thus captured explained the previous data of decreasing cell viability by treating with anti-diabetic drugs. The data was collected after treating the cells for 72 h with or without drugs. However, the 100 μM treatment (panel E) showed some irregular chromatin staining that certainly suggests that sitagliptin 100 μM dose has potential cytotoxic effects that induced cell death. Although, the affectivity is much lower than that of metformin 1 mM dosage in MCF7 cells. 
AnnexinV-FITC/PI binding study explains the apoptogenic potentiality against cancer cells by the anti-diabetic drugs
In case of both drugs, two doses, including the one similar to the clinical dose, had been used to investigate the pro-apoptogenic potential of the anti-diabetic drugs.
After 72 hours of treatment, metformin 1mM and pioglitazone 10 & 50 μM significantly reduced the number of normal cells and increased with the similar proportion the early and late apoptotic cells. Table-2 and  table-3 shows the effect of metformin, sitagliptin and pioglitazone on MCF-7 and HepG2 cells. Figure 4. 2), nearly similar scenario was observed with treated and untreated population. After 72 hours, the data was collected by flow cytometric analysis. Compared to the untreated control cells, the metformin 100 μM and 1 mM reduced cell pool in normal cell population and increased in early apoptotic cell populations significantly to 2.97%±0.08 and 5.28%±0.44 from 0.09%±0.02 in the untreated control group. Sitagliptin also induced apoptosis but not in a dose dependent manner as in the case of metformin, and increased the early apoptotic cell population to 2.6±0.13 and 2.52±0.37 by 10 μM and 100 μM doses respectively. Eventually the similar sort of significant increase in the population of late apoptotic population was observed with all similar treatment groups.
Protein expression data explains the anti-proliferative role of the drugs
To investigate regarding the molecular mechanisms behind the anti-cancer potentials of the anti-diabetic drugs of our concern in this particular study, we targeted a few growthregulating molecules. We choose to study some basic protein expressions that could justify the role of the drugs in this context. Cell cycle regulatory protein: Cell cycle regulatory proteins' expression were investigated and compared for both anti-diabetic drugs. p21 Cip1 (alternatively p21 Waf1 ), p27 kip1 and CDK-4 were among the common proteins which were tested in both the cell lines ( Figure 5 ). 
PCNA:
Caspase-3 study resolves the apoptogenic potential of the drugs
To know if the drugs enhance the apoptotic mechanisms of the cancer cell lines (MCF7 and HepG2) the caspase-3 expression study was performed using Sigma Caspase 3 Assay Kit (Sigma-Aldrich, USA). Figure 6 demonstrates the outcome of the assay.
Panel A clearly states that when MCF7 cells were treated with sitagliptin (100 μM) and metformin (1 mM), the cells were potentially induced to activate their caspase-3 activity. From the Panel B, it was clear that sitagliptin and metformin also enhanced caspase-3 activity in HepG2 cells.
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DISCUSSION
In current era, established drugs and other pharmacological substances, known to be useful against diseases, are being unveiled to use their unknown therapeutic potentials in various other pathophysiological conditions. Complexity and intracellular signalling meshwork and exclusive responsive behaviour of the pharmacological agents in any specific tissue are opening up newer uses other than their current use. In line with the same conception, herein, we are assessing the anti-cancer potencies of a useful type-2 anti-diabetic drug sitagliptin in comparison with another drug, metformin, a biguanide. Since investigators from different parts of the globe have demonstrated through pre-clinical in vivo and in vitro studies about increased pro-cancerous changes with the use of insulin or insulin secretagogues (sulfonylurea), the other anti-diabetics required a reconsideration regarding their use against cancer. In line with this, in our previous investigation it was shown that pioglitazone can reduce MCF7 cancer growth through sustained activation of MAPK in a PPARγ independent pathway. It has been put forward for the first time before the scientific community that in MCF7 cells pioglitazone can utilize the ERK1/2 phosphorylation as a tool to inhibit cancer growth 2 .
Several scientific interpretations have indicated about the hostile effects of using agonists of GLP-1 pathway 12, 13, 14 . The hazard of pancreatic cancer and pancreatitis is reported to be higher in individuals with diabetes and obesity than in the healthy people. The fact has been found that GLP-1 receptor (GLP-1R) activation inspires calcitonin secretion and countersigns the expansion of C-cell hyperplasia and medullary thyroid cancer (MTC) in rodents. Cases of depression have also been reported. Sitagliptin sometimes increases creatinine levels 15 . Pharmacological data suggest there might be an increased risk of cancer and muscular and neurological disorders. In contrast, we found out that sitagliptin, an agonist of GLP-1, could induce the p21 and p27 expression up to a certain extent in MCF7 cell line. This shows the sign of anti-cancer potentials of sitagliptin. Anti-proliferative character of the drug was also supported by the fact that treatment with the same could significantly decrease the expression of PCNA (proliferating cell nuclear antigen) in both cell lines. As stated earlier, sitagliptin had no supporting anti-cancer properties, rather it induced inflammation in certain tissues 16 but our present data was in line with our recent review which illustrated various beneficial effects of the drug as well 17 . 22 but no evidence has been suggested regarding its efficacy in modulating the in vitro cell signaling thereby stopping cell proliferation. Whereas, we have found out an apoptogenic behaviour in sitagliptin when treated against MCF7 breast cancer cell lines and HepG2 liver cancer cell line. These observations have been reported for the first time in similar circumstances. In our study we demonstrated that though a lower than that of metformin but certain impact of sitagliptin on early apoptogenic efficacy in HepG2 and late apoptogenic efficacy on MCF7 as well as the caspase-3 activity expression in both cell lines.
DPP4
promoted EGF-induced epithelial cell transformation and mammary tumorigenesis via induction of PIN1 expression, suggesting that sitagliptin targeting of DPP4 could be a treatment strategy in patients with breast cancer 23 . In line with the previous finding, we showed for the first time that, Sitagliptin could induce an anti-cancer mechanism that in turn could significantly induce p21 and p27 expression in MCF7 breast cancer cell and suppressed PCNA , has been observed to show cell-death inducing characters.
In conclusion, we found sitagliptin to show a potential cytotoxic effect on both type of cancer cells (MCF7 and HepG2). It has also showed certain impact on early apoptogenic efficacy in HepG2 and late apoptogenic efficacy on MCF7 as well as the caspase-3 activity expression in both cell lines. In the line of our study it might be concluded that sitagliptin has a potent anticancerous activity, though it was observed to be lesser than that of metformin, though further investigation is needed to establish its potentiality as a useful drug for the diabetic cancer condition patients.
